Citations

Clear

350 citation(s) found for "Stevens, V".

The Relationship between Training and Mental Health among Caregivers of Individuals with Polytrauma
Stevens, Lillian Flores , Pickett, Treven C. , Schaaf, Kathryn P. Wilder, Taylor, Brent C , Gravely, Amy , Houtven, Courtney H. Van , Friedemann‐Sánchez, Greta , Griffin, Joan M.

Mayo Clinic

Behavioural Neurology | December 8, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-13

10.1155/2015/185941 | PMID 26770015 Get It

This was a hypothesis-generating exploration of relationships between caregiver training during TBI/polytrauma rehabilitation and caregiver mental health. In this cross-sectional study, 507 informal caregivers to US service members with TBI who received inpatient rehabilitation care in a Veterans Affairs’ Polytrauma Rehabilitation Center from 2001 to 2009 completed a retrospective, self-report survey. Embedded in the survey were measures of caregiver mental health, including the National Institutes of Health’s Patient Reported Outcome Measurement Information System (PROMIS) Anxiety and Depression Short Forms, the Rosenberg Self-Esteem scale, and the Zarit Burden Short Form. Though no groups endorsed clinical levels, mental health symptoms varied by caregiver training category (Trained, Not Trained, and Did Not Need Training). Caregivers who did not receive training on how to navigate healthcare systems endorsed higher depression and burden and lower self-esteem than those who did. Caregivers who did not receive training in supporting their care recipients’ emotions endorsed higher anxiety, depression, and burden and lower self-esteem than those who did. Analyses also suggested a different association between training and mental health based on caregivers’ relationship to the care recipient and the intensity of care recipient needs. Potential hypotheses for testing in future studies raised by these findings are discussed.
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
Shen, Ying , Nitta, Masayuki, Futalan, Diahnn, Treiber, Jeffrey M. , Taich, Zack, Stevens, Deanna M., Wykosky, Jill, Chen, Hong-Zhuan, Becher, Oren J. , Kennedy, Richard D. , Cavenee, Webster K. , Desai, Arshad , Chen, Clark C. , Li, Jie , Steed, Tyler , Taich, Zack, Carter, Bob S. , Esashi, Fumiko , Sarkaria, Jann N. , Furnari, Frank B.

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 14 | Pages: 11751-11767

10.18632/oncotarget.3996 | PMID 26059434 Get It

Genome-Wide Association Study of Prostate Cancer–Specific Survival
Szulkin, Robert , Whitington, Thomas, Aly, Markus , Grönberg, Henrik , Eeles, Rosalind A. , Easton, Douglas F. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Giles, Graham G. , Southey, Melissa C. , FitzGerald, Liesel M. , Henderson, Brian E., Schumacher, Fredrick R. , Haiman, Christopher A. , Sipeky, Csilla , Tammela, Teuvo L.J. , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Donovan, Jenny , Hamdy, Freddie C. , Pashayan, Nora , Stanford, Janet L. , Thibodeau, Stephen N. , McDonnell, Shannon K. , Schaid, Daniel J. , Maier, Christiane, Vogel, Walther , Luedeke, Manuel, Herkommer, Kathleen , Kibel, Adam S. , Lubiński, Jan , Kluźniak, Wojciech , Cannon‐Albright, Lisa , Brenner, Hermann , Herrmann, Volker, Holleczek, Bernd , Sellers, Thomas A. , Lim, Hui-Yi, Kaneva, Radka , Mitev, Vanio , Teixeira, Manuel R. , Paulo, Paula , Maia, Sofia , Pandha, Hardev , Michael, Agnieszka , Batra, Jyotsna , Clements, Judith A. , BioResource, on behalf of the Australian Prostate Cancer, Albanes, Demetrius, Andriole, Gerald L. , Berndt, Sonja I., Gapstur, Susan M. , Giovannucci, Edward L. , Ma, Jing , Mondul, Alison M. , Stampfer, Meir J. , Stevens, Victoria L. , Weinstein, Stephanie J. , Trichopoulou, Antonia , Bueno-de-Mesquita, Bas H., Tjønneland, Anne , Cox, David G. , Mæhle, Lovise, Schleutker, Johanna , Lindström, Sara , Karlsson, Robert , Kote‐Jarai, Zsofia , Key, Tim , Pharoah, Paul D.P. , Khaw, Kay‐Tee , Cybulski, Cezary , Park, Jong Y. , Slavov, Chavdar , Spurdle, Amanda B. , Kierzek, Andrzej , BioResource, on behalf of the Australian Prostate Cancer, Berndt, Sonja I. , Chanock, Stephen Jacob , Hunter, David J. , Kraft, Peter , Marchand, Loı̈c Le , Penney, Kathryn , Wiklund, Fredrik E. , Giles, Graham G , Teixeira, Manuel R , Eeles, Rosalind A , Southey, Melissa C , Tjønneland, Anne , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Cannon-Albright, Lisa A , Michael, Agnieszka , Brenner, Hermann , Batra, Jyotsna , Clements, Judith , Lubinski, Jan , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 25, 2015 | Volume: 24 | Issue: 11 | Pages: 1796-1800

10.1158/1055-9965.epi-15-0543 | PMID 26307654 Get It

Abstract Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. Cancer Epidemiol Biomarkers Prev; 24(11); 1796–800. ©2015 AACR.
Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism
Borgeson, Daniel D., STEVENS, Tracy L., Heublein, Denise M., Matsuda, Yuzuru, Burnett, John C. , Stevens, Tracy L.

Mayo Clinic

Clinical Science | August 7, 2015 | Volume: 95 | Issue: 2 | Pages: 195-202

10.1042/cs0950195 Get It

1.A family of structurally related but genetically distinct natriuretic peptides exist which include atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) of myocardial cell origin and C-type natriuretic peptide (CNP) of endothelial and renal epithelial cell origin. All three exert actions via cGMP, with ANP and BNP functioning via the natriuretic peptide A receptor and CNP via the natriuretic peptide B receptor. 2.Circulating and urinary natriuretic peptides were determined in response to acute intravascular volume overload (AVO). Additionally, their functional role in cardiorenal regulation during AVO was investigated by utilizing the natriuretic peptide receptor antagonist HS-142-1. Control (n = 5) and study dogs (HS-142-1, n = 9) underwent AVO with normal saline equal to 10% of body weight over 1 ;h. Both groups demonstrated similar significant increases in right atrial pressure, pulmonary capillary wedge pressure, pulmonary artery pressure and cardiac output. Circulating ANP paralleled increases in right atrial pressure and pulmonary capillary wedge pressure, with no changes in plasma BNP or CNP. At peak AVO, urinary CNP excretion was increased compared with baseline (7.0±4.2 versus 62±8.0 ;pg/min, P< 0.05). 3.In the HS-142-1-treated group, plasma cGMP was decreased compared with the control group (9.6±1.1 to 5.0±1.2 ;pmol/ml, P< 0.05). A significant attenuation of natriuresis (566±91 versus 1241±198 ;μEq/min, P< 0.05) and diuresis (4.8±0.7 versus 10.1±2.0 ;ml/min, P< 0.05) was also observed at peak AVO in the HS-142-1 treated group. 4.These findings support differential and selective responses of the three natriuretic peptides to AVO, in which plasma ANP and urinary CNP are markers for AVO. Secondly, these studies confirm the role of ANP and CNP but not BNP in the natriuretic and diuretic response to acute volume overload.
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2
Jack, Clifford R. , Barnes, Josephine , Bernstein, Matt A. , Borowski, Bret, Brewer, James, Clegg, Shona , Dale, Anders M. , Carmichael, Owen , Ching, Christopher R. K. , DeCarli, Charles , Desikan, Rahul S. , Fennema‐Notestine, Christine , Fjell, Anders M. , Fox, Nick C. , Gunter, Jeff, Holland, Dominic , Hua, Xue , Kantarci, Kejal , Krueger, Gunnar, Leung, Kelvin K., Mackin, Scott, Maillard, Pauline , Malone, Ian B. , Mattsson, Niklas , McEvoy, Linda K. , Modat, Marc , Mueller, Susanne G. , Nosheny, Rachel L. , Ourselin, Sébastien , Schuff, Norbert, Senjem, Matthew L. , Simonson, Alix, Thompson, Paul M. , Rettmann, Dan , Vemuri, Prashanthi , Walhovd, Kristine B. , Zhao, Yansong , Zuk, Samantha M., Weiner, Michael W. , DeCarli, Charles , Borowski, Bret J, Zuk, Samantha, Fletcher, Evan M. , Gutman, Boris A , Insel, Philip S. , Killiany, Ronald , Bernstein, Matt A , Jack, Clifford R , Vemuri, Prashanthi , Dale, Anders M , Thompson, Paul M , Senjem, Matthew L , Ching, Christopher R K , Kantarci, Kejal , Fox, Nick C , Maillard, Pauline

Mayo Clinic

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 740-756

10.1016/j.jalz.2015.05.002 | PMID 26194310 Get It

AbstractIntroductionAlzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.MethodsWe review the contributions of the MRI core from present and past cycles of ADNI (ADNI‐1, ‐Grand Opportunity and ‐2). We also review plans for the future‐ADNI‐3.ResultsContributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.DiscussionOver the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.
A Pilot Study of Spirituality and Inpatient Rehabilitation Outcomes in Persons with Spinal Cord Dysfunction and Severe Neurological Illnesses
Piderman, Katherine M. , Mueller, Paul S. , Theneau, Terry M., Stevens, Susanna R., Hanson, Andrew C. , Reeves, Ronald K.

Mayo Clinic

Journal of Pastoral Care & Counseling: Advancing theory and professional practice through scholarly and reflective publicati | May 18, 2015 | Volume: 65 | Issue: 4 | Pages: 1-13

10.1177/154230501106500402 Get It

This prospective, observational pilot study was conducted on an academic inpatient rehabilitation unit. Ninety-three persons with spinal cord dysfunction or severe neurological illness participated. All completed admission surveys; 46 completed surveys six months after discharge. The aims were to describe admission and post-discharge spirituality and associations between spirituality and rehabilitation outcomes. At admission, participants reported spirituality similar to that of other samples of medical patients. After discharge, frequency of private spiritual practices increased and spiritual and existential well-being decreased. No significant associations were detected between spirituality and rehabilitation outcomes. Findings suggest the importance of spirituality to the participants and future research with a larger sample and modifications to the methodology.
Spiritual Well-Being and Spiritual Practices in Elderly Depressed Psychiatric Inpatients
Piderman, Katherine M. , Stevens, Susanna R., Somers, Kristin J., Kronberg, Matthew T., Clark, Matthew M. , Rummans, Teresa A. , Lapid, Maria I. , Ryan, Susan

Mayo Clinic

Journal of Pastoral Care & Counseling: Advancing theory and professional practice through scholarly and reflective publicati | May 18, 2015 | Volume: 65 | Issue: 1 | Pages: 1-11

10.1177/154230501106500103 | PMID 22452149 Get It

This study's aims were to describe the spirituality of depressed elderly psychiatric inpatients and to examine associations among spirituality, depression, and quality of life (QOL). Forty-five persons participated. Most reported frequent, stable spiritual practices and experiencing spiritual comfort and guidance. Some reported spiritual distress and changes in spirituality. During hospitalization, participants demonstrated increased spiritual well-being (SWB) and peacefulness, and reduced hopelessness, worthlessness, and guilt. Positive associations were found between SWB and QOL and negative associations between SWB and depression.
Abstract 2737: Modulation of mitotic DNA damage as a paradigm for glioblastoma therapy
Shen, Ying , Nitta, Masayuki, Futalan, Diahnn, Taich, Zack, Treiber, Jeffrey M. , Stevens, Deanna M., Chen, Hongzhuan , Wakosky, Jill, Chen, Clark C. , Li, Jie , Steed, Tyler , Taich, Zack, Schroeder, Mark A. , Sarkaria, Jann N. , Jiang, Tao , Carter, Bob S. , Esashi, Fumiko , Furnari, Frank B. , Cavenee, Webster K. , Desai, Arshad

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 2737-2737

10.1158/1538-7445.am2014-2737 Get It

Abstract The clinical efficacies of molecularly targeted glioblastomas therapies have been vastly disappointing. The multitudes of resistance mechanisms suggest that glioblastomas possess highly dynamic molecular circuits grounded in functional redundancy. Emerging data suggests that the expression of functionally redundant oncogenes induced similar forms of cellular stress, requiring hyper-activation of common compensatory pathways to ensure cell viability. Targeting these pathways, therefore, afford potential opportunities for tumor ablation while by-passing the redundancy of oncogenic circuitry. To explore this paradigm, we carried out a siRNA screen to identify synthetic lethal partners of the oncogenic Epidermal Growth Factor Receptor variant III (EGFRvIII) in glioblastoma cells and identified Polo-Like Kinase 1 (PLK1). Treatment using a PLK1 inhibitor, BI2536, or siRNAs induced preferential toxicity to the EGFRvIII expressing glioblastoma cells in multiple in vitro (serum and neurosphere lines) and in vivo models (heterotopic and orthotopic xenograft models). Consistent with the heightened PLK1 requirement, EGFRvIII expressing glioblastomas harbored increased levels of the p-Thr210 PLK1 (an activated form of PLK1). Inhibition of PLK1 by BI2536 treatment induced an increase in the proportion of cells that co-stained for p-Histone H3 and γH2AX foci, suggesting accumulation of mitotic DNA damage. This effect was exacerbated by EGFRvIII expression, implicating induction of mitotic DNA damage as a major contributor to the observed synthetic lethality. Consistent with this observation, EGFRvIII expression induced the formation of aberrant mitosis as well as prolonged mitotic progression. Further supporting an essential role for PLK1 in suppressing DNA damage accumulation, BI2536 treatment significantly enhanced the tumoricidal effect of the DNA damaging chemotherapy, temozolomide. Mechanistically, inhibition of PLK1 suppressed the expression of Rad51, the accumulation of pS14 Rad51 (an active form of Rad51), as well as overall homologous recombination efficiency in vitro. We validated the clinical pertinence of these results using three clinically annotated glioblastoma databases (TCGA, REMEBMRANDT, CGGA). In all three datasets, increased expression of a PLK1 signature consistently associated with increased expression of HR genes and lowered gene expression signature associated with DNA damage accumulation. Supporting our proposed paradigm, the tumoricidal effect of BI2536 was universally observed in a panel of eight murine ink4a/arf (-/-) EGFRvIII expressing glioblastoma clones that developed resistance to EGFR inhibitors by distinct and independent mechanisms. In aggregate, our results support the essential role of PLK1 in suppressing mitotic DNA damage and provide a novel framework for glioblastoma therapy. Citation Format: Ying Shen, Masayuki Nitta, Jie Li, Diahnn Futalan, Tyler Steed, Zack Taich, Jeffrey M. Treiber, Deanna Stevens, Mark A. Schroeder, Jann N. Sarkaria, Hong-Zhuan Chen, Tao Jiang, Bob S. Carter, Fumiko Esashi, Jill Wakosky, Frank Furnari, Webster K. Cavenee, Arshad Desai, Clark C. Chen. Modulation of mitotic DNA damage as a paradigm for glioblastoma therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2737. doi:10.1158/1538-7445.AM2014-2737
Sex differences in elite swimming with advanced age are less than marathon running
Senefeld, Jonathon W. , Joyner, Michael J. , Stevens, Alyssa , Hunter, Sandra K. , Hunter, Sandra K , Joyner, Michael J , Senefeld, Jonathon W

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | February 4, 2015 | Volume: 26 | Issue: 1 | Pages: 17-28

10.1111/sms.12412 | PMID 25648250 Get It

The sex difference in marathon performance increases with finishing place and age of the runner but whether this occurs among swimmers is unknown. The purpose was to compare sex differences in swimming velocity across world record place (1st–10th), age group (25–89 years), and event distance. We also compared sex differences between freestyle swimming and marathon running. The world's top 10 swimming times of both sexes for World Championship freestyle stroke, backstroke, breaststroke, and butterfly events and the world's top 10 marathon times in 5‐year age groups were obtained. Men were faster than women for freestyle (12.4 ± 4.2%), backstroke (12.8 ± 3.0%), and breaststroke (14.5 ± 3.2%), with the greatest sex differences for butterfly (16.7 ± 5.5%). The sex difference in swimming velocity increased across world record place for freestyle (P < 0.001), breaststroke, and butterfly for all age groups and distances (P < 0.001) because of a greater relative drop‐off between first and 10th place for women. The sex difference in marathon running increased with the world record place and the sex difference for marathon running was greater than for swimming (P < 0.001). The sex difference in swimming increased with world record place and age, but was less than for marathon running. Collectively, these results suggest more depth in women's swimming than marathon running.
Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project
Ringold, Sarah , Hendrickson, Audrey, Abramson, Leslie, Beukelman, Timothy , Blier, Peter R., Bohnsack, John F. , Chalom, Elizabeth, Gewanter, Harry L., Gottlieb, Beth S. , Hollister, Roger, Hsu, Joyce , Hudgins, Andrea, Klein‐Gitelman, Marisa, Lindsley, Carol B., Lopez‐Benitez, Jorge M. , Lovell, Daniel J. , Mason, Tom, Milojevic, Diana , Moorthy, Lakshmi N., Nanda, Kabita , Onel, Karen , Rabinovich, C. Egla, Ray, Linda, Rouster‐Stevens, Kelly , Ruth, Natasha M. , Shishov, Michael , Spalding, Steven J., Syed, Reema , Vehe, Richard K. , Weiss, Jennifer E. , White, Andrew J. , Wallace, Carol A., Sobel, Rachel E. , Ilowite, Norman T. , Moorthy, L. Nandini , Prahalad, Sampath , Stoll, Matthew Laurence , White, Andrew J

Mayo Clinic

Arthritis Care & Research | October 20, 2014 | Volume: 67 | Issue: 4 | Pages: 529-537

10.1002/acr.22487 | PMID 25331530 Get It

ObjectiveFew data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.MethodsParticipating physicians were surveyed monthly to ascertain whether their JIA patients experienced an SAE or IME. Sites were surveyed every 6 months to determine the number of unique JIA patients seen at each site during that 6‐month period. Reporting rates were calculated per 100 person‐years and 95% confidence intervals (95% CIs) were calculated based on a Poisson distribution.ResultsThirty‐seven Childhood Arthritis and Rheumatology Research Alliance sites with 115 physicians participated. The mean response rate to the monthly surveys was 65%. There were 147 total SAEs and 145 total IMEs. The largest proportion of SAEs and IMEs occurred in children with polyarticular JIA (39% and 37%, respectively). The majority of SAEs and IMEs were reported for patients receiving therapy with biologic agents (76% and 69%, respectively). The total event rate for SAEs and IMEs combined was 1.07 events per 100 person‐years (95% CI 0.95–1.19). The rates for SAEs and IMEs were 0.54 per 100 person‐years (95% CI 0.45–0.63) and 0.53 per 100 person‐years (95% CI 0.49–0.62), respectively.ConclusionThe EDSSP provided a simple tool for SAE/IME reporting within an established research network and resulted in a similar range of reported events as captured by a traditional product‐based registry.